[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moderate-to-severe-psoriasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moderate-to-severe-psoriasis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100621449","impact-of-tildrakizumab-on-patient-reported-outcomes-in-patients-with-moderate-to-severe-psoriasis-in-canada-100621449",false,"NCT07370766","Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada","A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada","PRO\u002FPsO","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Diagnosis of moderate-to-severe chronic plaque-type PsO with Fitzpatrick scale type III or above (BSA \\>\u002F=3%).\n3. Candidate for phototherapy and\u002For systemic therapy.\n4. Planning to initiate tildrakizumab as part of routine clinical care through the ILUMYA SUPPORT® Program for the treatment of plaque PsO but has not yet received their first dose.\n\n   a. Decision to treat with tildrakizumab must be made independently of and prior to study recruitment.\n5. Must be able to read, understand, and communicate in English.\n6. Must be willing to participate in the study and capable to provide informed consent\n7. Able to comply with all study procedures and attend all study visits\n\nExclusion Criteria:\n\n1. Known hypersensitivity to tildrakizumab, its excipients, or components of the container, as outlined in the Product Monograph.\n2. Concurrently taking any oral medication for treatment of PsO (e.g. methotrexate, cyclosporin, acitretin)\n3. Diagnosis of only palmoplantar psoriasis\n4. Concurrent medical condition or significant comorbidities that, in the investigator's opinion, would prevent participation in the study or interfere with study assessments\n5. Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding.\n6. Prior (within 30 days) or actively participating in other interventional clinical trial(s).\n7. Unable or unwilling to comply with study procedures including completing questionnaire.\n8. Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","OBSERVATIONAL","This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale skin types III and above.\n\nThe real-world impact, safety and effectiveness of tildrakizumab on patients with moderate-to-severe plaque psoriasis (PsO) remain largely undocumented in Canada, despite its approval in 2018. Given Canada's diverse population, this study presents an opportunity to evaluate tildrakizumab's quality of life, safety and effectiveness in specific demographic groups, particularly those patients with Fitzpatrick scale skin type III and above.\n\nThe findings from this study will help optimize care, address unmet needs, and ensure that treatment outcomes are inclusive and reflective of Canada's diverse population.",[25,26],"Psoriasis (PsO)","Moderate to Severe Psoriasis",[28,29,30,31,32],"psoriasis","moderate to severe psoriasis","Fitzpatrick scale","tildrakizumab","patient reported outcomes","RECRUITING","2026-01-20",{"date":36,"type":37},"2026-01-27","ACTUAL",{"date":39,"type":37},"2025-11-25",{"date":41,"type":21},"2027-05-30",{"name":43,"class":44},"Chronicle Academy","OTHER",6,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100528831","the-relationship-between-moderate-to-severe-psoriasis-and-sleep-disturbance-100528831","NCT06165887","The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance","The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance: a Prospective Cohort Study","Inclusion Criteria:\n\n1. In line with the diagnostic criteria of psoriasis\n2. PASI\\>10 or BSA\\>10%\n3. Understand and agree to participate in this study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Those with serious mental diseases, such as depression, anxiety, etc;\n2. PSQI\\>5 points;\n3. Long term use of sedative and hypnotic drugs;\n4. Patients with diabetes mellitus or severe heart, liver and kidney disease;\n5. Those diagnosed with sleep disorders, such as apnea syndrome, periodic limb movement disorder, restless legs syndrome, narcolepsy, etc;\n6. There are serious cardiovascular and cerebrovascular diseases, respiratory system diseases, and immune system diseases;\n7. Pregnant women during pregnancy, lactation, or planned trials;\n8. Those who have participated in other clinical studies or are participating in other clinical trials within 3 months;\n9. Unable to cooperate with the study for any reason, such as the following situation: language understanding, unable to complete the scale tester.\n\nIf any one of the above items is met, it shall be excluded.",true,"65 Years",{"count":56,"type":21},156,"Psoriasis is a common chronic and systemic immune-mediated disease, induced by a combination of genetic and environmental effects. The increasingly worrying question is the negative impact on patients' sleep, which has become an important comorbidity of psoriasis. To investigate the causal relationship between psoriasis and sleep status, a prospective cohort study will be conducted by separating moderate-to-severe psoriasis patients and healthy individuals into distinct cohorts in order to observe their sleep status.",[59],"Moderate-to-severe Psoriasis","NOT_YET_RECRUITING","2024-02-20",{"date":63,"type":37},"2024-02-21",{"date":65,"type":21},"2024-02",{"date":67,"type":21},"2026-06",{"name":69,"class":44},"Shanghai Yueyang Integrated Medicine Hospital",1]